Product image of Levosimendan Waymade (Levosimendan) supplied by GNH India

Levosimendan Waymade

Active Ingredient:
Levosimendan
Origin:
EU

Levosimendan Waymade (Levosimendan)

Levosimendan, the active ingredient in Levosimendan Waymade, is a calcium sensitizer presented as an intravenous formulation for IV use. It is indicated for the treatment of acute decompensated heart failure in adult patients, where it improves cardiac contractility without raising intracellular calcium levels.\n\nGNH India supplies Levosimendan Waymade as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Waymade B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Levosimendan is used in the management of heart failure syndromes where enhanced cardiac output is needed.\n\nAcute decompensated heart failure: improves cardiac output and relieves symptoms of congestion.\nCardiogenic shock: provides inotropic support while maintaining myocardial oxygen consumption.\nPost‑cardiac surgery low‑output syndrome: stabilises haemodynamics and facilitates weaning from mechanical support.

How It Works

  • Levosimendan binds to cardiac troponin C in a calcium‑dependent manner, increasing the sensitivity of the contractile apparatus to existing calcium ions. It also opens ATP‑dependent potassium channels in vascular smooth muscle, causing vasodilation. These combined actions enhance myocardial contractility and reduce after‑load without raising intracellular calcium concentration, thereby improving cardiac output with a lower risk of calcium‑mediated toxicity.

Side Effects

  • Levosimendan may be associated with several adverse reactions that clinicians monitor during therapy.\n\nCommon Side Effects:\n- Hypotension: reduction in systolic blood pressure, especially during initial infusion.\n- Headache: mild to moderate intensity, often transient.\n- Nausea or vomiting: gastrointestinal discomfort during or after infusion.\n- Tachycardia: increased heart rate, usually dose‑related.\n- Flushing: warm sensation and reddening of skin.\n\nSerious or Rare Side Effects:\n- Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.\n- Severe hypotension: marked drop in blood pressure requiring intervention.\n- Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion.\n- Anaphylactoid reactions: rare allergic responses with rash, bronchospasm, or hypotension.

Precautions & Warnings

  • Levosimendan requires careful monitoring and specific precautions to ensure safe use.\n\nBlood pressure monitoring: observe for hypotension during and after infusion.\nCardiac rhythm surveillance: continuous ECG to detect arrhythmias.\nRenal function assessment: adjust use in severe renal impairment.\nAvoid in severe hypotension: contraindicated when systolic BP <90 mmHg.\nContraindicated in mechanical obstruction: do not use in patients with significant outflow tract obstruction.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

  • Levosimendan may interact with other cardiovascular agents, requiring dose adjustments or monitoring.\n\nMajor Interactions (Avoid):\n- Concurrent use with other potent vasodilators: risk of profound hypotension.\n- Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations.\n\nModerate Interactions (Monitor Closely):\n- Beta‑blockers: may blunt the positive inotropic effect.\n- Diuretics: additive effect on blood pressure and electrolyte balance.\n- Calcium channel blockers: potential for enhanced vasodilation and hypotension.

Frequently Asked Questions

Levosimendan Waymade is used to treat acute decompensated heart failure in adult patients. It improves cardiac contractility and reduces symptoms by sensitising the heart muscle to calcium and causing vasodilation, helping to restore adequate blood flow without increasing intracellular calcium levels.

Levosimendan binds to cardiac troponin C, increasing the sensitivity of the contractile proteins to existing calcium, which enhances heart muscle contraction. It also opens ATP‑dependent potassium channels in vascular smooth muscle, producing vasodilation and reducing the workload on the heart.

The dosing regimen for Levosimendan Waymade is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response to therapy. Healthcare professionals set the infusion rate and duration according to approved guidelines and individual patient needs.

Safety data for levosimendan in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Unlike traditional catecholamine inotropes, levosimendan enhances contractility without raising intracellular calcium, which may reduce the risk of calcium‑mediated toxicity. It also provides vasodilation through potassium‑channel opening, offering a dual mechanism that can be advantageous in certain heart‑failure scenarios.

Levosimendan Waymade should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Maintaining the cold‑chain ensures stability and potency of the intravenous solution until it is administered.

Levosimendan Waymade is given by intravenous infusion. The infusion is typically started under continuous haemodynamic monitoring in a hospital setting, allowing clinicians to adjust the rate based on blood pressure, heart rate, and overall response.

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare anaphylactoid reactions. Patients receiving levosimendan should be closely monitored for these events, especially during the initial infusion period.

Levosimendan is contraindicated in patients with systolic blood pressure below 90 mmHg, significant outflow tract obstruction, or known hypersensitivity to the drug. Caution is also advised in severe renal impairment and in those taking other potent vasodilators.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Levosimendan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT